Alnylam Pharmaceuticals, Inc. (ALNY)

Market Cap	35.67B
Revenue (ttm)	2.35B
Net Income (ttm)	-269.70M
Shares Out	130.39M
EPS (ttm)	-2.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,233,429
Open	258.40
Previous Close	259.39
Day's Range	258.40 - 273.87
52-Week Range	144.73 - 304.39
Beta	0.17
Analysts	Strong Buy
Price Target	324.54 (+18.64%)
Earnings Date	May 1, 2025

About ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2004
• Employees: 2,230
• Stock Exchange: NASDAQ
• Ticker Symbol: ALNY
• Website: https://www.alnylam.com

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Analyst Forecast

According to 25 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price forecast is $324.54, which is an increase of 18.64% from the latest price.

Price Target

$324.54

(18.64% upside)

Analyst Consensus: Strong Buy